Class information for:
Level 1: CONDITIONAL POWER//INTERIM ANALYSIS//SAMPLE SIZE RE ESTIMATION

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
2373 2197 22.0 60%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
970 10197 CAUSAL INFERENCE//PRINCIPAL STRATIFICATION//STATISTICS IN MEDICINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CONDITIONAL POWER Author keyword 152 85% 4% 80
2 INTERIM ANALYSIS Author keyword 143 66% 6% 131
3 SAMPLE SIZE RE ESTIMATION Author keyword 114 88% 2% 53
4 ADAPTIVE DESIGN Author keyword 100 45% 8% 166
5 GROUP SEQUENTIAL DESIGN Author keyword 83 82% 2% 49
6 INTERIM ANALYSES Author keyword 82 86% 2% 42
7 GROUP SEQUENTIAL TEST Author keyword 71 84% 2% 38
8 SAMPLE SIZE REESTIMATION Author keyword 68 100% 1% 22
9 GROUP SEQUENTIAL TESTS Author keyword 65 93% 1% 25
10 INTERNAL PILOT STUDY Author keyword 53 89% 1% 24

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CONDITIONAL POWER 152 85% 4% 80 Search CONDITIONAL+POWER Search CONDITIONAL+POWER
2 INTERIM ANALYSIS 143 66% 6% 131 Search INTERIM+ANALYSIS Search INTERIM+ANALYSIS
3 SAMPLE SIZE RE ESTIMATION 114 88% 2% 53 Search SAMPLE+SIZE+RE+ESTIMATION Search SAMPLE+SIZE+RE+ESTIMATION
4 ADAPTIVE DESIGN 100 45% 8% 166 Search ADAPTIVE+DESIGN Search ADAPTIVE+DESIGN
5 GROUP SEQUENTIAL DESIGN 83 82% 2% 49 Search GROUP+SEQUENTIAL+DESIGN Search GROUP+SEQUENTIAL+DESIGN
6 INTERIM ANALYSES 82 86% 2% 42 Search INTERIM+ANALYSES Search INTERIM+ANALYSES
7 GROUP SEQUENTIAL TEST 71 84% 2% 38 Search GROUP+SEQUENTIAL+TEST Search GROUP+SEQUENTIAL+TEST
8 SAMPLE SIZE REESTIMATION 68 100% 1% 22 Search SAMPLE+SIZE+REESTIMATION Search SAMPLE+SIZE+REESTIMATION
9 GROUP SEQUENTIAL TESTS 65 93% 1% 25 Search GROUP+SEQUENTIAL+TESTS Search GROUP+SEQUENTIAL+TESTS
10 INTERNAL PILOT STUDY 53 89% 1% 24 Search INTERNAL+PILOT+STUDY Search INTERNAL+PILOT+STUDY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 INTERIM ANALYSES 172 80% 5% 106
2 CONDITIONAL POWER 145 90% 3% 63
3 SAMPLE SIZE REESTIMATION 118 95% 2% 39
4 GROUP SEQUENTIAL DESIGNS 91 89% 2% 41
5 HYPOTHESES SELECTION 91 94% 1% 32
6 I ERROR RATE 67 77% 2% 46
7 GROUP SEQUENTIAL METHODS 67 80% 2% 41
8 2 STAGE DESIGNS 65 60% 3% 71
9 GROUP SEQUENTIAL TESTS 57 95% 1% 19
10 REESTIMATION 49 78% 1% 32

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 JOURNAL OF BIOPHARMACEUTICAL STATISTICS 23 16% 6% 130
2 PHARMACEUTICAL STATISTICS 16 18% 4% 81
3 CONTROLLED CLINICAL TRIALS 16 12% 5% 120
4 CLINICAL TRIALS 7 11% 3% 67
5 STATISTICS IN BIOPHARMACEUTICAL RESEARCH 7 16% 2% 39

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects Systematic Review and Meta-regression Analysis 2010 154 16 81%
Adaptive clinical trials in oncology 2012 45 13 38%
Adaptive design methods in clinical trials - a review 2008 76 37 73%
Adaptive trial designs: a review of barriers and opportunities 2012 22 54 59%
Adaptive Clinical Trial Design 2014 5 25 52%
Randomized trials stopped early for benefit - A systematic review 2005 341 13 31%
Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative 2015 2 28 18%
Adaptive Trial Designs 2012 7 18 100%
Bayesian clinical trials 2006 184 13 31%
An introduction to adaptive designs and adaptation in CNS trials 2011 8 14 100%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 MED PHARMACEUT STAT UNIT 22 38% 2.1% 46
2 MED BIOMETRY UNIT 13 71% 0.5% 10
3 BIOMETR 1 9 36% 0.9% 20
4 COMPETENCE CLIN TRIALS 3 57% 0.2% 4
5 OB CDER 3 100% 0.1% 3
6 COMPETENCE CLIN TRIALS BREMEN 3 60% 0.1% 3
7 SECT QUANTITAT BIOL PL STAT 3 60% 0.1% 3
8 BIOMETRY MATH STAT BRANCH 2 18% 0.5% 12
9 STAT DRUG DEV 2 44% 0.2% 4
10 QUAL TEST CERTIFICAT 2 67% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000155174 INTERACTION CONDITION//TARGETED CLINICAL TRIALS//INFLUENCE CONDITION
2 0.0000151728 BEHRENS FISHER DISTRIBUTION//PILOT TRIALS//COPC
3 0.0000122006 RESPONSE ADAPTIVE DESIGN//DOUBLY ADAPTIVE BIASED COIN DESIGN//RESPONSE ADAPTIVE DESIGNS
4 0.0000106099 NON INFERIORITY MARGIN//NON INFERIORITY//THREE ARM DESIGN
5 0.0000103116 CONTINUAL REASSESSMENT METHOD//DOSE FINDING//DOSE FINDING STUDIES
6 0.0000091998 WORST RANK SCORES//REPRODUCIBILITY PROBABILITY//BOUNDED OUTCOME SCORES
7 0.0000087330 BRIDGING STUDY//MULTIREGIONAL CLINICAL TRIAL//MULTIREGIONAL TRIAL
8 0.0000068503 SURROGATE ENDPOINT//PRENTICE CRITERION//PRENTICE CRITERIA
9 0.0000067153 FALSE DISCOVERY RATE//MULTIPLE TESTING//FAMILYWISE ERROR RATE
10 0.0000066822 CRONYISM//PERFORMANCE ATTRIBUTIONS//ETHNOGRAPHY OF SPEAKING